Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px
Document › Details

Activaero GmbH. (4/23/13). "Press Release: Activaero and the University of Giessen Extend Strategic Research and Development Collaboration. Entirely New Approach to Treat Pulmonary Hypertension (PH)". Gemünden/Wohra.

Organisations Organisation Activaero GmbH
  Group Vectura (Group)
  Organisation 2 TransMIT Gesellschaft für Technologietransfer mbH
  Group University of Gießen (Justus Liebig University)
Products Product FAVORITE technology (Flow and VOlume Regulated Inhalation TEchnology)
  Product 2 pharmaceutical
Persons Person Scheuch, Gerhard (Activaero 201105 CEO + Founder)
  Person 2 Malfent, Lucia (MC Services 201211 before Intercell VP Global Head Corporate Communications)
     


> Molecule successfully used in other indications now for the first time enabled by Activaero´s FAVORITE inhalation to treat PH

> FAVORITE-based drug-device combination optimizes dosing, generates maximum efficacy and results in rapid treatment


Activaero GmbH, the therapeutic area specialist for respiratory diseases, today announced the signing of the extended collaboration agreement with TransMIT, Gesellschaft für Technologietransfer mbH, the technology transfer agency of Justus-Liebig-University Giessen. The new project covered under this agreement will extend the ongoing successful collaboration for the development of innovative therapies in the field of serious pulmonary diseases.

The collaboration is focused on an entirely new approach to the treatment of pulmonary hypertension. As part of this development program, Activaero´s FAVORITE inhalation approach (FAVORITE = Flow and Volume Controlled Inhalation Technology) will be used in combination with an undisclosed compound to treat PH. The goal of the planned development program is to precisely target the affected regions of the lung with an effective dose of the inhaled drug while keeping treatment times as short as possible. At present, the team at University Giessen is investigating this approach in cell cultures and animal models. First results are expected later this year.

"We are very pleased with our long-standing and mutually successful collaboration between Activaero and the University of Giessen. With the scientists there, we have strong and highly innovative partners, who have an unparalleled track record in developing new therapies and continuously improving the treatment of lung diseases," explained Dr. Gerhard Scheuch, Founder and CEO of Activaero GmbH. Based on the previous co-development efforts of the partnership, a scientifically and commercially very attractive product has already been generated for Activaero´s pipeline.

"By combining our knowledge with Activaero´s inhalation approach, there is a potential to provide pulmonary hypertension patients with new, more efficient and convenient treatment options. We expect that through precise drug targeting on the affected lung area as well as shortened inhalation times, we will gain improved results in therapy," commented Prof. Dr. Werner Seeger, Medical Director, University Hospital Giessen and Marburg GmbH.


Pulmonary Hypertension

Pulmonary hypertension is a life-threatening disorder, characterized by pathological changes of the pulmonary blood vessels, which lead to severe resistance and pressure increase in the pulmonary circulation. The flow of blood through the lung is disturbed; the right side of the heart is forced to work harder. Patients suffer from severely impaired physical capability, shortness of breath and circulatory disorders up to right heart failure. Pulmonary hypertension can occur without any recognizable cause; PH is, however, often secondary to other diseases, such as chronic obstructive pulmonary disease (COPD), chronic thromboembolism, lung fibrosis, sarcoidosis, HIV-infections, ARDS, sickle-cell anemia, scleroderma or congenital heart disease.

During recent years a number of therapies using new drugs to treat pulmonary hypertension have been developed - mostly with a significant contribution of University Giessen. Nevertheless, so far there is no lasting improvement or cure of this severe disease. As such, research in PH medical therapies is of great importance to the affected patients.


About FAVORITE

FAVORITE is Activaero's proprietary, clinically and commercially proven inhalation approach to effectively treat severe respiratory and pulmonary diseases. FAVORITE actively regulates inspiration flow and inhalation volume. By guiding, controlling and supporting the patient's breathing, optimal inhalation patterns are created. Using FAVORITE, inhaled drugs can be selectively targeted to pre-defined lung regions hence unlocking completely new opportunities for novel aerosol therapies.


About TransMIT

With approximately 155 employees TransMIT GmbH exploits and commercializes at the interface of economy and science the potential of about 6,000 scientists of several research institutions inside and outside Hessen. At present, 151 TransMIT Centres market innovative technologies and services of the Justus-Liebig University Giessen, Technical University Mittelhessen and Philipps University Marburg in the areas of biotechnology/chemistry/pharmacy, medicine and medical technology, technology, communications/media/literature, corporate governance and leadership, plus information and communication technologies. TransMIT was founded in 1996 as a joint project of central Hessian Universities, Volksbanken und Sparkassen as well as IHK Giessen-Friedberg.

TransMIT has offices in Marburg, Giessen, Friedberg and Frankfurt.


About Activaero

Activaero is a therapeutic area specialist developing treatment solutions for patients suffering from severe respiratory diseases, including Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis (CF), Idiopathic Pulmonary Fibrosis (IPF) and Pulmonary Hypertension. Activaero´s clinically proven treatment approach FAVORITE ensures highly efficient, targeted and safe local drug deposition in the lungs to fight severe respiratory diseases with dramatically better therapeutic outcomes. Activaero was founded in 1998 in Germany and is a privately held company with offices near Frankfurt and Munich in Germany as well as in Dublin, Ohio (USA).

For further information please visit:
www.activaero.de


Contact

Activaero GmbH
Dr. Gerhard Scheuch
Founder and Chief Executive Officer
t: +49-6453-64818-16
e: info@activaero.de
www.activaero.com

Media contact

Dr. Lucia Malfent
MC Services AG
t: +49-89-210228-36
e: lucia.malfent@mc-services.eu

   
Record changed: 2017-04-02

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for Vectura (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px




» top